Imeglimin as a Replacement Therapy for Metformin in Patients With Type 2 Diabetes Mellitus Experiencing Metformin Intolerance: A Retrospective Observational Study.

Cureus · 2026 · PMC13332843 · PMID 42403739

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In this regard, the 2% GI side effects with imeglimin in this study, compared with the 20%-30% rate with standard metformin, are highly significant and a finding consistent with its distinct mechanism of action [ 6 , 20 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.